Best of #ACR22 Day 2 in PSA -Efficacy and Safety Results from BE OPTIMAL in PsA -JAK inhibitors in rheumatic diseases
Tweet Content
Best of #ACR22 Day 2 in PSA
-Efficacy and Safety Results from BE OPTIMAL in PsA
-JAK inhibitors in rheumatic diseases
-Who is the Winner? Switch vs Cycle in PsA
-Women vs. Men: Response to Treatment in Seronegative Arthritis
and more.
https://t.co/JSKafxioMT https://t.co/Ov0VuCdX5y
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off